Evidence map›Paper›PMID 42118141›Full record

ArticleClinical and translational science2026

Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline-Induced Cardiotoxicity Using an Integrated PK/PD Model.

Mohamed S Dabour, Anne H Blaes, Pamala A Jacobson, Mark N Kirstein, Beshay N Zordoky, Shen Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed S DabourDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0001-9261-4234
Anne H BlaesDivision of Hematology/Oncology/Transplantation, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-5433-4810
Pamala A JacobsonDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-4145-7045
Mark N KirsteinDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-3486-083X
Beshay N ZordokyDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-9358-4185
Shen ChengDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-7493-4784

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX) is an effective chemotherapeutic agent; however, its use is limited by dose-dependent cardiotoxicity, which is challenging to detect early with current biomarkers such as NT-proBNP. Growth differentiation factor-15 (GDF15) has emerged as a promising cytokine associated with cardiovascular disease. This study aimed to develop a pharmacokinetic/pharmacodynamic (PK/PD) model describing the dynamic relationship between DOX and GDF15 in patients with breast cancer, compare GDF15 responses with NT-proBNP, and evaluate the prognostic utility of GDF15. Using plasma samples from 17 breast cancer patients who received two consecutive DOX cycles, the DOX-GDF15 PK/PD model was estimated in Monolix, using DOX empirical Bayes estimates from our published DOX-NT-proBNP PK/PD model. Simulations were then performed to compare exposure metrics (C

Indexed as

Antibiotics, AntineoplasticBreast NeoplasmsCardiotoxicityDoxorubicinGrowth Differentiation Factor 15Models, BiologicalAdultAgedBayes TheoremBiomarkersComputer SimulationFemaleHumansMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsAntibiotics, AntineoplasticBiomarkersDoxorubicinGDF15 protein, humanGrowth Differentiation Factor 15Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)anthracyclinescardiotoxicitydoxorubicinGDF15NT‐proBNPpharmacodynamic modeling

Identifiers

PMID42118141
PMCPMC13165276

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.